De Novo device
Tag-It Cystic Fibrosis Kit
Tm Bioscience Corporation · System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection (NUA, Class II) · First FDA decision May 9, 2005, newest Jun 7, 2006Genetic and newborn screening
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
223
Naming "Tag-It"
MAUDE reports
0
Brand "Tag-It", since 2015
PubMed studies
60
Mentioning "Tag-It"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Tag-It Cystic Fibrosis Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K060627 · Decided Jun 7, 2006 · 90 days after receipt
Device type: System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection (NUA) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Tag-It", any status and sponsor, newest update first.
- NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label DevicesNot yet recruiting
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07806149 · 200 participants (planned) · Start Nov 25, 2026 · Primary completion Mar 1, 2029
Device: SESAME Procedure · For: Hypertrophic Cardiomyopathy; Left Ventricular Outflow Obstruction; Systolic Anterior Motion
Sites: Washington D.C., District of Columbia; Atlanta, Georgia; Boston, Massachusetts · 8 sites in all
222 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Tag-It", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NUA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Tag-It"[tiab]. The summary above synthesizes these.
- Signature-tagged mutagenesis.
Bakshi S, Sun YH, Chalmers R, et al. · Methods Mol Med · 2001
- Bag it, tag it: ubiquitin ligases and host resistance to Mycobacterium tuberculosis.
Campos PC, Cunha DT, Souza-Costa LP, et al. · Trends Microbiol · 2022Review, Research Support, Non-U.S. Gov't
- Genome organization: Tag it, move it, place it.
Peng AYT, Kolhe JA, Behrens LD, et al. · Curr Opin Cell Biol · 2021Research Support, N.I.H., Extramural, Review
- Tag it.
Degnan B · JEMS · 2013Letter, Comment
- The effectiveness of short-format refutational fact-checks.
Ecker UKH, O'Reilly Z, Reid JS, et al. · Br J Psychol · 2020
- Using Imaging Flow Cytometry to Quantify Neutrophil Phagocytosis.
Smirnov A, Solga MD, Lannigan J, et al. · Methods Mol Biol · 2020Research Support, N.I.H., Extramural
- A new peptide-affinity tag for the detection and affinity purification of recombinant proteins with a monoclonal antibody.
Böldicke T, Struck F, Schaper F, et al. · J Immunol Methods · 2000Research Support, Non-U.S. Gov't
- Transgenic manipulation of triacylglycerol biosynthetic enzymes in B. napus alters lipid-associated gene expression and lipid metabolism.
Liao P, Lechon T, Romsdahl T, et al. · Sci Rep · 2022Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- Applications and prospects of genome editing in plant fatty acid and triacylglycerol biosynthesis.
Park ME, Kim HU · Front Plant Sci · 2022Review
- Separation of triacylglycerols containing positional isomers of hexadecenoic acids by enantiomeric liquid chromatography-mass spectrometry.
ezanka T, Lukavský J, Rozmo¡ M, et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2022
- An SPR-based analysis of cGAS substrate KD and steady-state KM values.
Ralph EC, Hall J · Methods Enzymol · 2019
- The N-terminal domain is required for cell surface localisation of VapA, a member of the Vap family of Rhodococcus equi virulence proteins.
Miranda-CasoLuengo R, Yerlikaya Z, Luo H, et al. · PLoS One · 2024Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NUA.
- xTAG Cystic Fibrosis 39 Kit v2Luminex Molecular Diagnostics, Inc. · 510(k) 2016
- Esensor Cystic Fibrosis Carrier Detection System, Model Esensor 4800Clinical Micro Sensors, Inc. · 510(k) 2006
- Xtag CF60 Kit V2Luminex Molecular Diagnostics, Inc. · 510(k) 2009
- Verigene Cftr Nucleic Acid Test and Verigene Cftr Polyt Nucleic Acid TestNanosphere, Inc. · 510(k) 2009
- Esensor Cf Genotyping Testm Esensor SystemOsmetech Molecular Diagnostics · 510(k) 2009
- Inplex Cf Molecular TestThird Wave Technologies, Inc. · 510(k) 2008
- Cystic Fibrosis Genotyping Assay, Model 6L20-01Celera Diagnostics · 510(k) 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.